What is AMBOSS?
Headquartered in Berlin, AMBOSS has fundamentally transformed how medical knowledge is acquired and applied at the point-of-care. The company operates a sophisticated knowledge platform that serves a dual purpose: providing medical students with an interactive library and high-yield question bank for rigorous exam preparation, while simultaneously offering clinicians evidence-based recommendations to facilitate effective decision-making. By bridging the gap between academic study and clinical application, AMBOSS has established itself as an essential tool for the medical community, driving efficiency and improving patient outcomes through technology-enabled insights.
How much funding has AMBOSS raised?
AMBOSS has raised a total of $298.6M across 3 funding rounds:
Series A
$5.6M
Series B
$33M
Other Financing Round
$260M
Series A (2017): $5.6M with participation from Cherry Ventures
Series B (2019): $33M led by Wellington Partners, Partech, Cherry Ventures, Target Global, and Holtzbrinck Digital
Other Financing Round (2025): $260M supported by Kirkbi, Lightrock, and M&G Investments
Key Investors in AMBOSS
Kirkbi
Kirkbi is a private holding and investment company that maintains majority ownership of the LEGO Group, focusing on sustainable long-term investments to secure the future of the brand.
Lightrock
Lightrock is a global sustainable investment platform managing over $5.5 billion in assets, dedicated to supporting purpose-driven businesses that address significant global challenges.
M&G Investments
M&G Investments is a Switzerland-based firm operating within the venture capital and private equity industry, providing strategic financial support to growth-stage enterprises.
What's next for AMBOSS?
With the successful closure of this major strategic investment, AMBOSS is well-positioned to accelerate its product development and market penetration. The company is expected to focus on enhancing its clinical decision support capabilities and expanding its footprint in international markets. As the healthcare industry increasingly prioritizes data-driven, evidence-based solutions, AMBOSS is poised to leverage its platform to address complex clinical challenges. The involvement of high-caliber institutional investors suggests a long-term commitment to scaling the platform's impact, potentially leading to further integration within hospital systems and medical institutions worldwide.
See full AMBOSS company page
